



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶:

C07D 215/54, A61K 31/47, C07D 241/44,
A61K 31/50, C07D 213/82, A61K 31/455,
C07D 217/26, 237/28, A61K 31/495,
C07D 307/85, A61K 31/34, C07D 333/70,
A61K 31/38, C07D 235/24, A61K 31/415,
C07D 241/24, 209/42, A61K 31/40, C07D
277/68, A61K 31/425, C07D 221/04,
213/81, 405/12, 401/12, 409/12, 417/12,
403/12, 471/04 // (C07D 471/04, 231:00,
221:00)

A1

(11) International Publication Number:

✓ WO 98/38167

(43) International Publication Date:

3 September 1998 (03.09.98)

990 3223-7
1P053
copy

(21) International Application Number: ✓ PCT/US98/01568

(22) International Filing Date: ✓ 5 February 1998 (05.02.98)

(30) Priority Data:

60/039,169 ✓

26 February 1997 (26.02.97) ✓ US

(71) Applicant (for all designated States except US): PFIZER INC.
[US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BROWN, Matthew, Frank
[US/US]; 66 Greenhaven Road, Pawcatuck, CT 06379 (US).
KATH, John, Charles [US/US]; 252 Shore Road, Waterford,
CT 06385 (US). POSS, Christopher, Stanley [US/US]; 10
Hermitage Drive, Gales Ferry, CT 06335 (US).

(74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., Patent Dept.,
235 East 42nd Street, New York, NY 10017 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR,
BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,
GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM,
KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
ML, MR, NE, SN, TD, TG).

Published


With international search report.

Before the expiration of the time limit for amending the
claims and to be republished in the event of the receipt of
amendments.

(54) Title: HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE
INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR ✓

(57) Abstract

Compounds of formula
(I) wherein R¹ is optionally
substituted (C₂-C₉)heteroaryl;
R² is optionally substi-
tuted phenyl-(CH₂)_m-,
naphthyl-(CH₂)_m-,
(C₃-C₁₀)cycloalkyl-(CH₂)_m-,
(C₁-C₆)alkyl or (C₂-C₉)heteroaryl-(CH₂)_m-, m is an integer from zero to four; R³ is hydrogen, or optionally substituted (C₁-C₁₀)alkyl,
(C₃-C₁₀)cycloalkyl-(CH₂)_n-, (C₂-C₉)heterocycloalkyl-(CH₂)_n-, (C₂-C₉)heteroaryl-(CH₂)_n- or aryl-(CH₂)_n-, n is an integer from zero to
six; or R³ and the carbon to which it is attached form an optionally substituted and/or fused five to seven membered carbocyclic ring; R⁴
is hydrogen, (C₁-C₆)alkyl, hydroxy, (C₁-C₆)alkoxy, hydroxy (C₁-C₆)alkyl, (C₁-C₆)alkoxyCO, (C₃-C₁₀)cycloalkyl-(CH₂)_p-, or optionally
substituted (C₂-C₉)heterocycloalkyl-(CH₂)_p-, (C₂-C₉)heteroaryl-(CH₂)_p-, phenyl-(CH₂)_p- or naphthyl-(CH₂)_p-, p is an integer from zero
to four; or R⁴ and R⁵ together with the nitrogen atom to which they are attached form an optionally substituted (C₂-C₉)heterocycloalkyl
group; R⁵ is hydrogen, (C₁-C₆)alkyl or amino. The present compounds are potent and selective inhibitors of MIP-1-alpha. binding to its
receptor CCR1, and are thus useful to treat inflammation and other immune disorders.



(I)